Clinical Trial News and Research

RSS

Novel imaging techniques improve post heart attack survival rates in mouse model

Human adult stem cells injected around the damage caused by a heart attack survived in the heart and improved its pumping efficiency for a year in a mouse model, researchers at The University of Texas MD Anderson Cancer Center report online ahead of publication in Circulation Research.

10 May 2010

Fibrinogen may reduce bleeding complications in cardiac surgery, says study

A joint clinical trial conducted by the University Hospital and the University of Gothenburg, Sweden, found that an element in human blood, fibrinogen, is likely more vital to the blood's clotting ability in connection with heart surgery than previously considered. If

10 May 2010

Researchers launch NIH-sponsored clinical trial for spinal deformity

Researchers at Northwestern Memorial have launched the first-ever National Institutes of Health-sponsored clinical trial for spinal deformity. The trial will evaluate the effectiveness of surgical and non-surgical treatments in people with adult scoliosis or curvature of the spine. Researchers also hope to identify important factors related to patient reported outcomes such as pain, activity and appearance.

7 May 2010

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

Threshold Pharmaceuticals, Inc., today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

CardioMEMS completes $37.9M financing

CardioMEMS, Inc., a medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced the completion of a $37.9M financing. The financing provides the company with capital to complete the company's CHAMPION clinical trial.

7 May 2010

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the first quarter of fiscal 2010.

7 May 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump.

7 May 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Halozyme Therapeutics first-quarter net loss decreases to $11.8 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the first quarter ended March 31, 2010. The Company also highlighted key commercial and regulatory progress during the quarter, and provided its expected milestones for the remainder of 2010.

7 May 2010

First clinical trial results of camera chip implanted under retina presented at 2010 ARVO meeting

Retina Implant, AG, a leading developer of subretinal implants for the visually impaired, today announced the presentation of findings from their first clinical trial in which blind patients were able to view and focus on objects as their eye and head naturally moved as opposed to needing to constantly move their head to scan a scene, which is the case for other implants in which a camera is mounted to the patient's head.

7 May 2010

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Gliomas arise from the supporting cells of the brain, called the glia. These cells are subdivided into astrocytes, ependymal cells and oligodendroglial cells (or oligos). These tumors are graded from the lowest grade 1 to highest grade 4, with glioblastoma multiforme being the highest grade and deadliest type of glioma.

7 May 2010

Medtronic initiates U.S. clinical trial of RestoreSensor neurostimulator in chronic pain patients

Medtronic, Inc. today announced the initiation of a prospective, multi-center, randomized U.S. clinical trial for the RestoreSensorTM neurostimulator that adapts therapy to the changing needs of chronic pain patients by responding automatically to changes in body position and activity in an upright position.

7 May 2010

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, reported today results for the recently completed Phase 2b non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801.

7 May 2010

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Keryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.

6 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

Cytochroma today announced positive Phase I results for CTAP201 Injection, a product being developed to treat secondary hyperparathyroidism in hemodialysis patients. The study demonstrated that single intravenous doses of 1 and 3 mcg of CTAP201 were safe and well tolerated. It also identified a starting dose of 2 mcg for subsequent pivotal trials intended to establish the product's safety and efficacy in the targeted population.

6 May 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.

6 May 2010

Curis reports net income of $4.8M for first-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2010.

6 May 2010

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

PurGenesis Technologies Inc. announced today positive results from a Phase I clinical trial on PUR0110, the Company's lead investigational new drug for the treatment of ulcerative colitis. This successful trial was designed to evaluate the safety and maximum tolerated dose of PUR0110.

6 May 2010

Clinical Trial News and Research

Novel imaging techniques improve post heart attack survival rates in mouse model

Fibrinogen may reduce bleeding complications in cardiac surgery, says study

Researchers launch NIH-sponsored clinical trial for spinal deformity

Threshold Pharmaceuticals reports $6.0M net loss for first-quarter 2010

CardioMEMS completes $37.9M financing

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Halozyme Therapeutics first-quarter net loss decreases to $11.8 million

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

First clinical trial results of camera chip implanted under retina presented at 2010 ARVO meeting

Researchers analyze relationship between extent of resection and outcome in patients with glioblastoma

Medtronic initiates U.S. clinical trial of RestoreSensor neurostimulator in chronic pain patients

Oramed reports Phase 2b non-FDA clinical trial results of ORMD-0801 oral insulin capsule

Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Cytochroma reports positive results from Phase I trial for CTAP201 Injection in hemodialysis patients

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Curis reports net income of $4.8M for first-quarter 2010

PurGenesis announces positive results from Phase I clinical trial of PUR0110 for ulcerative colitis

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer